Regulation of HIV-1 latency by T-cell activation
- PMID: 17643313
- PMCID: PMC2063506
- DOI: 10.1016/j.cyto.2007.05.017
Regulation of HIV-1 latency by T-cell activation
Abstract
HIV-infected patients harbor approximately 10(5)-10(6) memory CD4 T-cells that contain fully integrated but transcriptionally silent HIV proviruses. While small in number, these latently infected cells form a drug-insensitive reservoir that importantly contributes to the life-long persistence of HIV despite highly effective antiviral therapy. In tissue culture, latent HIV proviruses can be activated when their cellular hosts are exposed to select proinflammatory cytokines or their T-cell receptors are ligated. However, due to a lack of potency and/or dose-limiting toxicity, attempts to purge virus from this latent reservoir in vivo with immune-activating agents, such as anti-CD3 antibodies and IL-2, have failed. A deeper understanding of the molecular underpinnings of HIV latency is clearly required, including determining whether viral latency is actively reinforced by transcriptional repressors, defining which inducible host transcription factors most effectively antagonize latency, and elucidating the role of chromatin in viral latency. Only through such an improved understanding will it be possible to identify combination therapies that might allow complete purging of the latent reservoir and to realize the difficult and elusive goal of complete eradication of HIV in infected patients.
Figures



Similar articles
-
Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.mBio. 2018 Nov 13;9(6):e02158-18. doi: 10.1128/mBio.02158-18. mBio. 2018. PMID: 30425153 Free PMC article.
-
The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.J Virol. 2018 Jun 13;92(13):e02225-17. doi: 10.1128/JVI.02225-17. Print 2018 Jul 1. J Virol. 2018. PMID: 29643247 Free PMC article.
-
The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.Front Immunol. 2021 Aug 31;12:720697. doi: 10.3389/fimmu.2021.720697. eCollection 2021. Front Immunol. 2021. PMID: 34531866 Free PMC article.
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
-
Experimental approaches to the study of HIV-1 latency.Nat Rev Microbiol. 2007 Feb;5(2):95-106. doi: 10.1038/nrmicro1580. Nat Rev Microbiol. 2007. PMID: 17224919 Review.
Cited by
-
Endothelial cell stimulation overcomes restriction and promotes productive and latent HIV-1 infection of resting CD4+ T cells.J Virol. 2013 Sep;87(17):9768-79. doi: 10.1128/JVI.01478-13. Epub 2013 Jul 3. J Virol. 2013. PMID: 23824795 Free PMC article.
-
Reactivation of latent HIV by histone deacetylase inhibitors.Trends Microbiol. 2013 Jun;21(6):277-85. doi: 10.1016/j.tim.2013.02.005. Epub 2013 Mar 18. Trends Microbiol. 2013. PMID: 23517573 Free PMC article. Review.
-
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.Retrovirology. 2009 Dec 4;6:111. doi: 10.1186/1742-4690-6-111. Retrovirology. 2009. PMID: 19961595 Free PMC article. Review.
-
Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner.J Virol. 2014 Jul;88(13):7528-40. doi: 10.1128/JVI.00239-14. Epub 2014 Apr 23. J Virol. 2014. PMID: 24760882 Free PMC article.
-
Sulfonation pathway inhibitors block reactivation of latent HIV-1.Virology. 2014 Dec;471-473:1-12. doi: 10.1016/j.virol.2014.08.016. Epub 2014 Oct 11. Virology. 2014. PMID: 25310595 Free PMC article.
References
-
- Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188–91. - PubMed
-
- Chun TW, Davey RT, Jr, Ostrowski M, Shawn Justement J, Engel D, Mullins JI, et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med. 2000;6:757–61. - PubMed
-
- Schrager LK, D’Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. Jama. 1998;280:67–71. - PubMed
-
- Di Mascio M, Dornadula G, Zhang H, Sullivan J, Xu Y, Kulkosky J, et al. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months. J Virol. 2003;77:2271–5. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials